Clinical Trial Update: Daratumumab and Belatacept for Desensitization [Phase 1, Phase 2]

View source ↗

Summary

Ongoing Phase 1/2 clinical trials are evaluating the combination of daratumumab and belatacept for desensitization in highly sensitized kidney transplant recipi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• Belatacept (Nulojix) (belatacept)
• Daratumumab (daratumumab)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Highly Sensitized Prospective Kidney Transplant Recipients | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING